home / stock / knte / knte news

KNTE News and Press, Kinnate Biopharma Inc. From 05/12/22

Stock Information
Company Name: Kinnate Biopharma Inc.
Stock Symbol: KNTE
Market: NASDAQ
Website: kinnate.com
Menu
KNTE KNTE Quote KNTE Short KNTE News KNTE Articles KNTE Message Board
Get KNTE Alerts

News, Short Squeeze, Breakout and More Instantly...
KNTE - Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates

Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma ...
KNTE - Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors

Kinnate Biopharma (NASDAQ:KNTE) said the first patient began treatment in a phase 1 trial of KIN-3248 in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations. The company is exploring KIN-3248 as a next-generation pan-FGFR inhibitor for treating intrahepatic cho...

KNTE - Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...

KNTE - Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

SAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...
KNTE - MVIS, MRIN and CLVR among mid-day movers

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

KNTE - Kinnate Biopharma GAAP EPS of -$2.06 misses by $0.01

Kinnate Biopharma press release (NASDAQ:KNTE): FY GAAP EPS of -$2.06 misses by $0.01. As of December 31, 2021, the total of cash and cash equivalents and short-term investments was $324.9 million, exclusive of the joint venture’s cash. For further details see: Kinnate Biopharma G...

KNTE - Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mu...
KNTE - ISPO, DNAY and KNTE among after hour movers

Gainers: Semtech Corporation (NASDAQ:SMTC) +4%. Forterra (NASDAQ:FRTA) +4%. Cerus Corporation (NASDAQ:CERS) +4%. Inspirato Incorporated (NASDAQ:ISPO) +4%. Infinera Corporation (NASDAQ:INFN) +4%. Losers: Codex DNA (NASDAQ:DNAY) -6%. CureVac  (NASDAQ:CVAC) -5%. CarParts...

KNTE - Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting

SAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...

KNTE - Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress

Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnat...
Previous 10 Next 10